Accumulating evidence has demonstrated that aberrant activation of the noncanonical NF‐κB pathway is commonly observed in human malignancies [8, 9, 10, 11, 12, 13], including hematological and non‐hematological tumors, implying new regulatory roles for this pathway in cancer biology. The gene discussed is NFKB1; the disease is cancer.